Trading Signals: XLRN Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Nov. 19, 2021)(ACCELERON PHARMA INC)
| XLRN latest price $80.7800 (-3.37%) ($80.1000 - $84.1100) on Fri. Apr. 3, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.71% (three month average) | RSI | 60 | Latest Price | $80.7800(-3.37%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | XLRN declines -1.5% a day on average for past five trading days. | Weekly Trend | XLRN advances 7.2% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support XLRN advance at 0% a week (0% probability) XBI(58%) IBB(56%) ARKG(48%) ARKK(45%) VFMO(45%) | Factors Impacting XLRN price | XLRN will decline at least -3.855% in a week (0% probabilities). VXX(-32%) VIXM(-28%) UUP(-17%) TLT(-7%) SHY(3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.855% (StdDev 7.71%) | Hourly BBV | 0 () | Intraday Trend | -2.2% | | | |
|
5 Day Moving Average | $84.76(-4.7%) | 10 Day Moving Average | $82.46(-2.04%) | 20 Day Moving Average | $80.48(0.37%) | To recent high | -15.2% | To recent low | 58.5% | Market Cap | $4.376b | | | | Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. |